Takeaway
- Liquid and tissue biopsies can perform comparably in identifying patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/2 mutations who may benefit from poly (ADP-ribose) polymerase inhibition.
- Additionally, circulating tumor DNA (ctDNA) can detect novel androgen receptor (AR) variants possibly driving resistance to AR-signaling inhibitors.
Why this matters
- Although tissue...
